Effects of a modified Enzira® influenza vaccine, ver A

• Research type

  Research Study

• Full title

  A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL split virion, inactivated influenza vaccine in Healthy Volunteers aged 18-60 years (HMR code: 13-504).

• IRAS ID

  129249

• Contact name

  Frans van den Berg

• Contact email

  rec@hmrlondon.com

• Sponsor organisation

  bioCSL Pty Ltd

• Eudract number

  2013-001420-19

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  East Midlands - Leicester South Research Ethics Committee

• REC reference

  13/EM/0146

• Date of REC Opinion

  23 Apr 2013

• REC opinion

  Favourable Opinion